DrugPatentWatch Database Preview

RITALIN LA Drug Profile

« Back to Dashboard

Which patents cover Ritalin La, and what generic alternatives are available?

Ritalin La is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has one hundred and forty-two patent family members in thirty-three countries.

The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-one drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Summary for RITALIN LA

International Patents:	142
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	39
Clinical Trials:	99
Patent Applications:	4,049
Formulation / Manufacturing:	see details
Drug Prices:	see details
DailyMed Link:	RITALIN LA at DailyMed

Pharmacology for RITALIN LA

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Synonyms for RITALIN LA

113-45-1 (Parent)

2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride

2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride

2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R*,R*)-(+-)-

298-59-9

298M599

AC1L1SQ4

AC1Q5YRN

AK116471

AKOS016010356

alpha-phenyl-2-piperidineacetic acid methyl ester hydrochloride

AN-23356

API0003340

CAS-298-59-9

CC-30903

CCG-213572

CCRIS 6258

Centedrin

Centedrine

CHEBI:31836

CHEMBL1722

ciba 4311b

Concerta (TN)

CS-4658

D-erythro-Methylphenidate Hydrochloride

D01296

DSSTox_CID_886

DSSTox_GSID_20886

DSSTox_RID_75843

DTXSID8020886

EINECS 206-065-3

FT-0603372

FT-0672046

FT-0672047

H-Tic-OtBu.HCl

HE332528

HY-B1091A

JUMYIBMBTDDLNG-UHFFFAOYSA-N

LS-42

Medikinet

Meridil hydrochloride

Metadate

Metadate (TN)

Metadate CD

Metadate ER

Methyl .alpha.-phenyl-2-piperidineacetate hydrochloride

methyl 2-phenyl-2-(2-piperidyl)acetate hydrochloride

METHYL 2-PHENYL-2-(PIPERIDIN-2-YL)ACETATE HCL

Methyl 2-phenyl-2-(piperidin-2-yl)acetate hydrochloride

methyl 2-phenyl-2-piperidin-2-ylacetate hydrochloride

methyl alpha-phenyl-2-piperidine-acetate hydrochloride

Methyl alpha-phenyl-2-piperidineacetate hydrochloride

Methyl Phenidylacetate Hydrochloride

methyl phenyl(piperidin-2-yl)acetate hydrochloride

Methylin ER

Methylphenidan Hydrochloride

Methylphenidate (hydrochloride)

Methylphenidate HCl

METHYLPHENIDATE HYDROCHLORIDE

Methylphenidate hydrochloride (JAN/USP)

Methylphenidate hydrochloride [USAN:JAN]

Methylphenidate hydrochloride [USP:JAN]

Methylphenidate Hydrochloride ER

Methylphenidate hydrochloride solution, (Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material

Methylphenidate hydrochloride, European Pharmacopoeia (EP) Reference Standard

METHYLPHENIDATE HYDROCHLORIDE(SEE ALSO: METHYLPHENIDATE, CAS 113-45-1, NTPNO M20344)

Methylphenidate.HCl

Methylphenidate(Ritalin)

Methylphenidylacetate hydrochloride

Metilfenidat hydrochloride

MFCD00058191

MLS003922100

NCGC00091942-01

NCGC00257863-01

NSC 169868

NSC-169868

NSC-759278

NSC169868

NSC759278

Pharmakon1600-01505907

QuilliChew ER

Quillivant XR

Quillivant xr (TN)

Rilaline

Rilatine

Ritalin

Ritalin (TN)

Ritalin hy drochloride

Ritalin hydrochloride

Ritalin SR

Ritalin-SR

SC-83308

SCHEMBL41067

SMR000058998

threo-Methyl |A-phenyl-|A-(2-piperidyl)acetate hydrochloride

Tox21_111186

Tox21_200309

TRANSGENIC MODEL EVALUATION (METHYLPHENIDATE HYDROCHLORIDE) (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE)

WLN: T6MTJ BYR & VO1 & GH

US Patents and Regulatory Information for RITALIN LA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-004	Apr 10, 2004	AB1	RX	Yes	No			Y
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-003	Jun 5, 2002	AB1	RX	Yes	No			Y
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-001	Jun 5, 2002	AB1	RX	Yes	No			Y
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-002	Jun 5, 2002	AB1	RX	Yes	No			Y

Expired US Patents for RITALIN LA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-002	Jun 5, 2002
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-002	Jun 5, 2002
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-004	Apr 10, 2004
Novartis	RITALIN LA	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021284-001	Jun 5, 2002

Paragraph IV (Patent) Challenges for RITALIN LA

Drugname	Dosage	Strength	RLD	Submissiondate
	Extended-release Capsules	10 mg		2007-05-21
	Extended-release Capsules	20 mg, 30 mg and 40 mg		2006-08-21

Non-Orange Book US Patents for RITALIN LA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,902,742	Multiparticulate modified release composition
7,580,712	Wireless high-speed data network planning tool
6,730,325	Multiparticulate modified release composition
8,119,163	Nanoparticulate and controlled release compositions comprising cefditoren

International Patents for RITALIN LA

Country	Document Number	Estimated Expiration
European Patent Office	2020229
Brazil	PI0609982
Australia	2007260821
Cyprus	1110421